Literature DB >> 2753147

Characterization of DNA rearrangements of N-myc gene amplification in three neuroblastoma cell lines by pulsed-field gel electrophoresis.

H Kato1, K Okamura, Y Kurosawa, T Kishikawa, K Hashimoto.   

Abstract

We characterized N-myc gene amplification in three human neuroblastoma cell lines (IMR-32, TGW, GOTO). Rearrangements in long-range regions surrounding amplified N-myc genes were examined by pulsed-field gel electrophoresis. Since rare-cutting enzymes completely digested DNA at the middle of the N-myc gene, we were able to construct a physical map upstream and downstream of the germline N-myc gene, and to obtain information on restriction sites surrounding amplified N-myc genes. This method enables us to envisage the organization of amplified units over a long range. Digestion patterns differed considerably among the germline and the three cell lines, but were simple in each case. We estimated that the minimal distance between neighboring N-myc genes is at least several hundred kilobases. Our data suggest that amplification units contain several DNA fragments derived from different loci, but that they are homogeneous.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2753147     DOI: 10.1016/0014-5793(89)80790-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Cloning and physical mapping of DNA sequences encompassing a region in N-myc amplicons of a human neuroblastoma cell line.

Authors:  K Akiyama; Y Nishi
Journal:  Nucleic Acids Res       Date:  1991-12-25       Impact factor: 16.971

2.  Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma.

Authors:  Karin Melanie Cabanillas Stanchi; Gernot Bruchelt; Rupert Handgretinger; Ursula Holzer
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

3.  Expression of SMARCF1, a truncated form of SWI1, in neuroblastoma.

Authors:  T Takeuchi; S Nicole; A Misaki; M Furihata; J Iwata; H Sonobe; Y Ohtsuki
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  Megabase-scale analysis of the origin of N-myc amplicons in human neuroblastomas.

Authors:  K Akiyama; N Kanda; M Yamada; K Tadokoro; T Matsunaga; Y Nishi
Journal:  Nucleic Acids Res       Date:  1994-01-25       Impact factor: 16.971

5.  Combination of a synthetic retinoid and a DNA demethylating agent induced differentiation of neuroblastoma through retinoic acid signal reprogramming.

Authors:  Naoko Hattori; Kiyoshi Asada; Nozomu Miyajima; Akiko Mori; Yoko Nakanishi; Kana Kimura; Mika Wakabayashi; Hideyuki Takeshima; Chika Nitani; Junichi Hara; Toshikazu Ushijima
Journal:  Br J Cancer       Date:  2021-10-11       Impact factor: 9.075

6.  Characterization of N-myc amplification in a human neuroblastoma cell line by clones isolated following the phenol emulsion reassociation technique and by hexagonal field gel electrophoresis.

Authors:  Y Nishi; K Akiyama; B R Korf
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

7.  Isolation and structural analysis of a 1.2-megabase N-myc amplicon from a human neuroblastoma.

Authors:  S S Schneider; J L Hiemstra; B A Zehnbauer; P Taillon-Miller; D L Le Paslier; B Vogelstein; G M Brodeur
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

8.  Two transcription factors, E1AF and N-myc, correlate with the invasiveness of neuroblastoma cell lines.

Authors:  K Taguchi; K Yoshida; F Sasaki; K Fujinaga
Journal:  Jpn J Cancer Res       Date:  1997-04

9.  Identification and characterization of the human inhibitor of caspase-activated DNase gene promoter.

Authors:  Kazuhiko Omata; Ryosuke Suzuki; Takahiro Masaki; Tatsuo Miyamura; Tazuko Satoh; Tetsuro Suzuki
Journal:  Apoptosis       Date:  2008-07       Impact factor: 4.677

10.  Licochalcone A Inhibits BDNF and TrkB Gene Expression and Hypoxic Growth of Human Tumor Cell Lines.

Authors:  Michitsune Arita; Junichi Koike; Nobuji Yoshikawa; Motonari Kondo; Hiromichi Hemmi
Journal:  Int J Mol Sci       Date:  2020-01-13       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.